Recipharm, a global Contract Development and Manufacturing Organization, announced recently that it now owns 100% of GenIbet’s capital. This acquisition marks Recipharm’s entrance into the biopharmaceuticals market, benefiting from GenIbet’s path of innovation in this area. In turn, GenIbet can now profit from a more robust technological and industrial structure and from the parent company’s global reach.
With this operation, Portugal can also assume a more prominent role in the biotechnology sector, namely in terms of foreign investment, research, qualified employment and linkage to universities.
“We’ve enjoyed a great deal of success at GenIbet, and now is a fantastic time to be joining with Recipharm to share our expertise and broad service offer”, states Raquel Fortunato, the company CEO, in a news release issued in the company’s Linkedin page.
For his part, Mark Funk, Recipharm’s CEO, notes that “GenIbet is a leading player in this area and so we are proud to bring it into the Recipharm universe. We look forward to working closely together, building links with all of Recipharm in order to make this business a great success.”
GenIbet – a spin off company from iBET, the largest private Biotechnology Research Organization in Portugal, was the first biopharmaceutical company on the Iberian Peninsula with a GMP (Good Manufacturing Practices) certification, granted in 2009. Its 1st project was in the development and production of a typhoid fever vaccine, introduced by GVGH – a not-for-profit organization from GSK – in the Indian market in 2020. More recently, it has also played a crucial role in the development of mRNA technology, partnering with Moderna to take their very first mRNA vaccine in the clinic at the end of 2015.
Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. It has roughly 9000 employees spread across its headquarters in Stockholm (Sweden) and facilities in France, Germany, India, Israel, Italy, Portugal, Spain, United Kingdom and United States.
Until now, GenIbet’s capital was owned by iBet (49,66%), Medinfar (25,30%), Nutrinveste (12,88%) and Pentafar (11,15%).
Read more about the GenIbet acquisition by Recipharm:
Required Cookies The cookies allow to customize the commercial offers that are presented to you, considering your interests. They can be our own or third party cookies. Please, be advised that, even if you do not accept these cookies, you will receive commercial offers, but do not match your preferences.
Functional Cookies The cookies offer you a more complete and personalised experience, allowing to safe preferences, showing you relevant content to your liking and send you alerts you have requested.
Advertising Cookies These cookies offer the possibility to connect to social media and share content from our website.